Zymeworks halts development of cancer drug after trial setback-February 2024-www.financetom.com

Zymeworks halts development of cancer drug after trial setback

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Zymeworks halts development of cancer drug after trial setback

Sep 2, 2025 3:17 AM

Sept 2 (Reuters) - Zymeworks ( ZYME ) said on Tuesday it

will stop developing its experimental cancer drug after

early-stage trial results showed the treatment was unlikely to

meet the company's goals as a standalone therapy.

Previous page： Why Galera Therapeutics (GRTX) Stock Is Nosediving Next page： Babcock & Wilcox Enterprises to Proceed With Power Plant Conversion Project in Michigan

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Why Galera Therapeutics (GRTX) Stock Is Nosediving

Jun 3, 2024

Galera Therapeutics Inc ( GRTX ) shares are trading lower by 34.8% to $0.14 during Monday’s session after the company received a notice from Nasdaq’s Office of General Counsel stating that the Nasdaq Hearings Panel decided to delist the company’s shares due to non-compliance with Nasdaq’s continued listing standards. The company failed to meet the minimum average market value of...

Babcock & Wilcox Enterprises to Proceed With Power Plant Conversion Project in Michigan

Jun 3, 2024

11:14 AM EDT, 06/03/2024 (MT Newswires) -- Babcock & Wilcox Enterprises ( BW ) said Monday that it received a limited notice to proceed from NorthStar Clean Energy to start working on a Bioenergy with Carbon Capture and Storage conversion of a former coal-fired power plant in Michigan using its biomass SolveBright post-combustion carbon dioxide capture technology. The notice allows...

Why Lattice Semiconductor Shares Are Diving Premarket Today

Jun 3, 2024

Lattice Semiconductor Corporation ( LSCC ) shares are trading lower after the company announced that Jim Anderson decided to step down as president, CEO, and board member. The company announced the appointment of Esam Elashmawi, chief marketing and strategy officer, as Interim Chief Executive Officer, effective immediately. The board started a search process to identify a permanent CEO and will consider...

Neurogene's Gene Therapy For Rett Syndrome Picked For FDA Pilot Program

Jun 3, 2024

11:15 AM EDT, 06/03/2024 (MT Newswires) -- Neurogene ( NGNE ) said Monday that the US Food and Drug Administration selected the company's NGN-401 gene therapy for Rett syndrome for the support for clinical trials advancing rare disease therapeutics pilot program. Neurogene ( NGNE ) said it will have enhanced communications with the FDA to accelerate NGN-401 development as part...